Merck's injectable formulation of the blockbuster cancer immunotherapy Keytruda, branded Keytruda Qlex, has gained FDA approval. This new injectable form can be administered in minutes, significantly decreasing the 30-minute infusion time required for the original Keytruda infusion. Approval was granted based on clinical trial data demonstrating comparable safety and efficacy between the injectable and infused formulations. This advancement could streamline treatment delivery and improve patient convenience in oncology care.